Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Rhea-AI Summary
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) held its shareholders general meeting on June 25, 2026, in Paris at 2:30 p.m. CET.
Approximately 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board’s recommendations.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Peers on Argus
CLLS was down while close biotechnology peers showed mixed moves, and momentum data flagged only one peer up and one down, indicating a stock‑specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Clinical trial update | Positive | -2.8% | Final Phase 1 lasme-cel and preliminary eti-cel data presented at EHA 2026. |
| Jun 09 | Regulatory designation | Positive | +6.3% | FDA RMAT designation granted for lasme-cel in r/r B-ALL pivotal program. |
| Jun 03 | Capital/voting update | Neutral | +1.9% | Monthly disclosure of share count and total voting rights on Euronext Growth. |
| May 20 | Meeting announcement | Neutral | -3.8% | Announcement of annual shareholders general meeting scheduled for June 25, 2026. |
| May 12 | Clinical data preview | Positive | -0.5% | Planned EHA 2026 presentations on lasme-cel and eti-cel clinical datasets. |
Recent history shows mixed reactions, with some strong clinical and regulatory positives met by selling pressure.
Regulatory & Risk Context
Short interest is low, suggesting limited short-squeeze risk and a lower contribution of short positioning to day-to-day volatility.
An effective F-3 shelf registration through 2028 provides the company with flexibility to issue securities, which could be used for future financing or other corporate purposes.
Market Pulse Summary
This announcement confirms the annual meeting ran as planned, with about 55,84% of voting rights exercised and 29 resolutions adopted in line with board guidance. Investors may watch how existing capital authorizations and the F-3 shelf are used over time.
AI-generated analysis. Not financial advice.
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
At the meeting, during which approximately 55,
The detailed results of the vote and the resolutions are available on Cellectis’ website:
https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachments
